STL Index for: Nemolizumab

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

Update on Nemolizumab-ilto SC injection (Nemluvio®), Denileukin diftitox-cxdl IV use (Lymphir™), Deuruxolitinib phosphate tablets (Leqselvi™), Roflumilast cream (Zoryve™), Ustekinumab-ttwe SC/IV injectio (Pyzchiva®), Sofpironium gel, 12.45% (Sofdra™), Ustekinumab biosimilar (Steqeyma® SC/IV injection) and Lebrikizumab SC injection (Ebglyss™)

Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.